 STOCKHOLM, Jan. 9, 2023 PRNewswire BioArctic ABs publ Nasdaq Stockholm: BIOA B partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug Administration FDA has approved lecanemab-irmb1 Brand Name in the U.S.: LEQEMBITM 100 mgmL injection for intravenous use, a humanized immunoglobulin gamma 1 IgG1 monoclonal antibody directed against aggregated ...... 